Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tempest Therapeutics, Inc. Director's Dealing 2018

Dec 12, 2018

34632_dirs_2018-12-11_bdff7227-4542-4760-95f8-593ce95d4f62.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2018-12-07

Reporting Person: KOZIN MARC D (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-12-07 Common Stock A 831 $0.00 Acquired 7740 Direct

Footnotes

F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $5,000 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.